Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blin, J.
Right arrow Articles by Agid, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blin, J.
Right arrow Articles by Agid, Y.
NEUROLOGY 1988;38:1410
© 1988 American Academy of Neurology

Does levodopa aggravate Parkinson's disease?

Jérôme Blin, MD, Anne-Marie Bonnet, MD and Yves Agid, MD, PhD

Laboratoire de Médecine Eipérimentale and the Clinique de Neurologie et Neuropsychologie (Prof. F. Lhermitte), Hôpital de la Salpêtrière, Paris, France.

We studied the possible deleterious effect of levodopa therapy on 185 patients with Parkinson's disease and concluded that the time when levodopa is introduced, the daily dose, and the duration of treatment do not aggravate Parkinson's disease. We also studied 72 parkinsonian patients with levodopa-induced abnormal involuntary movements to see whether early initiation of levodopa therapy affected the time of onset of abnormal involuntary movements. The results suggested that it did not, and that levodopa was started early in these patients because of the severity of their motor disability.

Address correspondence and reprint requests to Dr. Agid, Laboratoire de Medecine Expérimentale, INSERM U 289, Hôpital de la Salpêtriere, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13 France.

Received September 2, 1987. Accepted for publication in final form January 27, 1988.




This article has been cited by other articles:


Home page
 BrainHome page
A. Schrag and N. Quinn
Dyskinesias and motor fluctuations in Parkinson's disease: A community-based study
Brain, November 1, 2000; 123(11): 2297 - 2305.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Barone, D. Bravi, F. Bermejo-Pareja, R. Marconi, J. Kulisevsky, S. Malagu, R. Weiser, and N. Rost
Pergolide monotherapy in the treatment of early PD: A randomized, controlled study
Neurology, August 1, 1999; 53(3): 573 - 573.
[Abstract] [Full Text]

Home page
 BrainHome page
P. Krack, P. Pollak, P. Limousin, A. Benazzouz, G. Deuschl, and A.-L. Benabid
From off-period dystonia to peak-dose chorea: The clinical spectrum of varying subthalamic nucleus activity
Brain, June 1, 1999; 122(6): 1133 - 1146.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. Fahn
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Arch Neurol, May 1, 1999; 56(5): 529 - 535.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
K. D. Sethi, C. F. O'Brien, J. P. Hammerstad, C. H. Adler, T. L. Davis, R. L. Taylor, J. Sanchez-Ramos, J. M. Bertoni, R. A. Hauser, and for the Ropinirole Study Group
Ropinirole for the Treatment of Early Parkinson Disease: A 12-Month Experience
Arch Neurol, September 1, 1998; 55(9): 1211 - 1216.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
G. W. Paulson
Therapy of Patients With Parkinson's Disease
Arch Neurol, August 1, 1994; 51(8): 754 - 756.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.